Report for: Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

Title	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Published in	PLOS ONE, February 2012
DOI	10.1371/journal.pone.0026331
Pubmed ID	22347360
Authors	Chandrajit P. Raut, Yves Boucher, Dan G. Duda, Jeffrey A. Morgan, Richard Quek, Marek Ancukiewicz, Johanna Lahdenranta, J. Paul Eder, George D. Demetri, Rakesh K. Jain
Abstract	Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density.

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Unknown	1	100%

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
United States	1	2%
Unknown	50	98%

Readers by professional status	Count	As %
Researcher	10	20%
Student > Ph. D. Student	8	16%
Student > Bachelor	5	10%
Student > Master	4	8%
Other	4	8%
Other	8	16%
Unknown	12	24%

Readers by discipline	Count	As %
Medicine and Dentistry	15	29%
Engineering	6	12%
Agricultural and Biological Sciences	5	10%
Biochemistry, Genetics and Molecular Biology	4	8%
Pharmacology, Toxicology and Pharmaceutical Science	2	4%
Other	4	8%
Unknown	15	29%

PLOS